NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 276)
Posted On: 04/21/2021 4:40:44 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of its Helomics subsidiary, Mark Collins, joined the latest episode to discuss updates on POAI’s financial footing, current operations and goals for 2021. “We are in a great situation, probably the best situation that we’ve been in since the existence of the company in terms of our cash capability and the strength of our balance sheet,” Myers said. “We have absolutely no liabilities other than your normal accounts payable, which are quite low. We have a lot of things going on in terms of the income that we expect to get this year and the projects that we have. I think that we are going into these projects in a strong position.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of its Helomics subsidiary, Mark Collins, joined the latest episode to discuss updates on POAI’s financial footing, current operations and goals for 2021. “We are in a great situation, probably the best situation that we’ve been in since the existence of the company in terms of our cash capability and the strength of our balance sheet,” Myers said. “We have absolutely no liabilities other than your normal accounts payable, which are quite low. We have a lot of things going on in terms of the income that we expect to get this year and the projects that we have. I think that we are going into these projects in a strong position.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼